Comparative Cell Surface Proteomic Analysis of the Primary Human T Cell and Monocyte Responses to Type I Interferon by Soday, Lior et al.
Frontiers in Immunology | www.frontiersin.
Edited by:
Timothy B. Niewold,
New York University, United States
Reviewed by:
Inger Øynebråten,
Oslo University Hospital, Norway
Nicola Tamassia,




†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Molecular Innate Immunity,
a section of the journal
Frontiers in Immunology
Received: 28 August 2020
Accepted: 13 January 2021
Published: 08 February 2021
Citation:
Soday L, Potts M, Hunter LM,
Ravenhill BJ, Houghton JW,
Williamson JC, Antrobus R, Wills MR,
Matheson NJ and Weekes MP (2021)
Comparative Cell Surface Proteomic
Analysis of the Primary
Human T Cell and Monocyte




published: 08 February 2021
doi: 10.3389/fimmu.2021.600056Comparative Cell Surface Proteomic
Analysis of the Primary Human T Cell
and Monocyte Responses to
Type I Interferon
Lior Soday1, Martin Potts1,2†, Leah M. Hunter1†, Benjamin J. Ravenhill 1,
Jack W. Houghton1, James C. Williamson1, Robin Antrobus1, Mark R. Wills2,
Nicholas J. Matheson3,4 and Michael P. Weekes1*
1 Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom, 2 Department of
Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom, 3 Cambridge Institute of
Therapeutic Immunology & Infectious Disease (CITIID), University of Cambridge, Cambridge, United Kingdom,
4 NHS Blood and Transplant, Cambridge, United Kingdom
The cellular response to interferon (IFN) is essential for antiviral immunity, IFN-based
therapy and IFN-related disease. The plasma membrane (PM) provides a critical interface
between the cell and its environment, and is the initial portal of entry for viruses.
Nonetheless, the effect of IFN on PM proteins is surprisingly poorly understood, and
has not been systematically investigated in primary immune cells. Here, we use
multiplexed proteomics to quantify IFNa2a-stimulated PM protein changes in primary
human CD14+ monocytes and CD4+ T cells from five donors, quantifying 606 and 482
PM proteins respectively. Comparison of cell surface proteomes revealed a remarkable
invariance between donors in the overall composition of the cell surface from each cell
type, but a marked donor-to-donor variability in the effects of IFNa2a. Furthermore,
whereas only 2.7% of quantified proteins were consistently upregulated by IFNa2a at the
surface of CD4+ T cells, 6.8% of proteins were consistently upregulated in primary
monocytes, suggesting that the magnitude of the IFNa2a response varies according to
cell type. Among these differentially regulated proteins, we found the viral target
Endothelin-converting enzyme 1 (ECE1) to be an IFNa2a-stimulated protein exclusively
upregulated at the surface of CD4+ T cells. We therefore provide a comprehensive map of
the cell surface of IFNa2a-stimulated primary human immune cells, including previously
uncharacterized interferon stimulated genes (ISGs) and candidate antiviral factors.
Keywords: type I interferon (IFN), leukocytes, quantitative proteomics, cell surface, antiviral restrictin, monocyte,
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Interferons (IFN) were discovered in 1957 and have since
become recognized as key components of antiviral immunity
in almost all cell types (1). Early detection of viruses by cellular
receptors triggers synthesis of type I (a/b) IFNs, which signal via
the ubiquitously expressed type I IFN receptor (IFNAR). There
are 12 subtypes of IFNa expressed in humans, which have a
similar structure, highly conserved protein sequence and bind
the same receptor. Differences are thought to arise at the level of
receptor binding affinity, which may lead to variation in the
magnitude of stimulation of target IFN-stimulated genes (ISGs)
(2, 3). The canonical signaling pathway includes activation of
JAK-STAT proteins, culminating in the transcription of an array
of ISGs, many of which exhibit antiviral function. IFNs also
orchestrate adaptive immune responses, enhancing T, B and
natural killer cell function in addition to both positively and
negatively regulating the IFN response itself (4).
Susceptibility to viral infection and disease is determined in
part by certain ISGs, the IFN-stimulated antiviral restriction
factors (ARFs) (5). However, different subsets of ISGs can be
induced in different cell types (6, 7), partly determined by the
density of IFN receptor expression, together with the pattern of
expression of kinases, STAT proteins and transcription factors
(8–10). Detailed characterization of the IFN response at the level
of individual cell types is thus essential, and the study of primary
as opposed to cultured cells has been instrumental in revealing
novel facets of antiviral immunity (11–13). Primary CD4+ T cells
and monocytes are particularly important, since they can not
only be infected by viruses, but also play key roles in immunity to
pathogens. Small-molecule disruption of the interaction between
ARFs and viral antagonists can enable endogenous inhibition of
viral replication (14), so identification and characterization of
novel ARFs in these cells may facilitate the development of new
antiviral therapies.
As well as the antiviral response, IFNs are critical for the
pathogenesis of autoimmune diseases including systemic lupus
erythematosus and interferonopathies such as Aicardi-Goutieres
syndrome (15). In addition, IFNa2 has been used to treat
cancers, multiple sclerosis and certain viral infections,
including chronic hepatitis B and coronavirus disease 2019
(COVID-19) (16–20). Treatment may be accompanied by
significant side-effects, and identifying candidate biomarkers
to predict the likelihood of response or adverse effects
from IFNa therapy would rationalize individualized therapy
(21). IFNa2a was therefore selected for this study both as a
representative of the IFNas, and due to its relevance to currently
employed therapeutics.
While previous studies have examined the effects of IFN
stimulation in primary leukocytes at the transcriptomic level
(6, 22), the correlation between transcript and protein abundance
is often poor (23–25). Proteomic investigations in these cells
have been limited by the available technology; for example, two-
dimensional gel electrophoresis detected only seven proteins
differentially expressed upon IFN stimulation of activated
CD4+ T cells (26). Beyond the whole cell proteome, the PM
represents a critical interface between the cell and itsFrontiers in Immunology | www.frontiersin.org 2environment, and is the site of many drug targets. However,
there have been no prior investigations of IFN-mediated protein
changes at the PM.
We previously developed ‘plasma membrane profiling’ to
enable quantitative investigation of cell surface proteomic
changes in response to viral infection (27, 28). In this study,
we adapt this technology to characterize the effects of IFNa2a at
the surface of primary monocytes and CD4+ T cells. By
multiplexing analysis using tandem mass tag (TMT)-based
triple-stage mass spectrometry, we provide a comprehensive
assessment of IFN-stimulated and unstimulated samples from
five donors, including quantification of 606 and 482 annotated
PM proteins in primary CD14+ monocytes and CD4+ T cells
respectively. We further show how the effect of IFNa2a varies
markedly between cell types and individuals, and identify ECE1
as a novel cell type-specific IFN-stimulated factor.MATERIALS AND METHODS
Primary Cell Isolation and Cell Culture
Primary Cell Isolation and Extraction for Proteomics
PBMCs were isolated by Ficoll density gradient centrifugation,
from leukocyte cones purchased from the national health service
blood and transplant service (NHSBT) in the case of monocytes,
and peripheral blood for enrichment of CD4+ T cells.
Enrichment of particular cell types from the PBMCs was by
negative selection using the MACS Monocyte Isolation Kit II
(Miltenyi Biotec, 130-091-153), Pan Monocyte Isolation Kit
(Miltenyi Biotec, 130-096-537) and Dynabeads Untouched
Human CD4 T Cells kit (Invitrogen, 11346D), according to the
manufacturer’s instructions.
Monocytes and pan-monocytes were cultured overnight in X-
Vivo 15 serum-free hematopoietic cell medium (Lonza), and
CD4+ T cells were cultured in RPMI-1640 medium (Sigma)
supplemented with 10% human AB serum (Sigma). The cells
were either left unstimulated or treated with 1600 IU/ml IFNa2a
for the CD14+ monocytes, or 1,000 IU/ml IFNa2a for pan-
monocytes and CD4+ T cells. A very similar breadth and depth
of response to IFNa2a stimulation was seen in whole pan-
monocyte samples (1,000 IU/ml) compared to CD14+
monocytes (1,600 IU/ml) (Figure S4A), and use of criteria
based on identifying proteins modulated >1 SD above or below
mean fold change as opposed to enforcing a single absolute fold
change across all cell types should mitigate effects due to different
IFN concentrations. All cells were cultured at 37˚C in 5% CO2.
IFNa2a for the proteomic experiments and some validation
was purchased from Reagent Proteins, a division of Pfenex Inc
(catalog number BCA-309). Additional IFNa2a for further
validation experiments was purchased from PBL Assay Science
(catalog number 11100-1). In both cases, the recombinant
protein was produced in E. coli, and the gene obtained from
human leukocytes, with the specific activity determined by the
supplier. In the case of the Reagent Protein IFN, activity was
determined in a viral resistance assay using bovine kidney
MDBK cells. Purity was >98% as determined by RP-HPLC andFebruary 2021 | Volume 12 | Article 600056
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cytopathic inhibition assay on MDBK cells with Vesicular
Stomatis Virus, and on human lung adenocarcinoma cell line
A549 with encephalomyocarditis virus. Purity was >95% by SDS-
PAGE stained by Coomassie Blue. No further additional tests for
LPS or other contaminants were detailed by the suppliers.
Primary Cell Isolation and Extraction for
Validation Experiments
For the validation experiments shown in Figures 5B, C, F, G, J,
primary cell enrichment and culture was as described above. For
additional experiments in Figures 5E, H, and Figures S5B and
S7, primary cells were enriched as follows. PBMCs were isolated
from venous blood samples by density gradient centrifugation
using Histopaque-1077 Hybri-Max (Sigma). Cells were isolated
from donor PBMCs using MACS CD14 MicroBeads (Miltenyi,
130-050-201) or MACS CD4 T cell Isolation Kit (Miltenyi, 130-
096-533), and an AutoMACS Pro Separator. For Figure S5A,
CD4 isolation was carried out using CD4 MicroBeads (Miltenyi,
130-045-101). Both CD14+ monocytes and CD4+ T cells were
incubated in X-Vivo 15 media.
Ethical Approval
For experiments relating to Figures 5E, H and Figures S5, S7,
donors were recruited locally following informed consent with
the ethical approval from the Cambridge Central Research Ethics
Committee REC reference (97/092). For all other experiments
ethical approval was granted by the University of Cambridge
Human Biology Research Ethics Committee (HBREC.2016.011)
and written informed consent was obtained from volunteers
prior to blood donations.
Cultured Cell Lines
THP-1, Jurkat and SUPT1 cells were maintained in RPMI-1640
medium (Sigma) supplemented with 10% FBS. All cells were
cultured at 37°C in 5% CO2. THP-1 cells were kindly provided
by Professor Paul Lehner (Department of Medicine, University
of Cambridge). All IFN stimulation of cultured cell lines was with
1,000 IU/ml IFNa2a.Plasma Membrane Enrichment
and Proteomics
Plasma Membrane Enrichment
Plasma membrane profiling was performed as described
previously (29, 30). Briefly, cells were centrifuged to collect and
washed twice with ice-cold PBS with MgCl2 and CaCl2 (Sigma).
An oxidation/biotinylation mix comprising 1 mM sodium meta-
periodate (Thermo), 100 mM aminooxy-biotin (Biotium) and 10
mM aniline (Acros Organics) in ice-cold PBS pH 6.7 was applied.
The samples were rocked for 30 min at 4°C in the dark, and then
the reaction was quenched with 1 mM glycerol for 5 min on ice.
Biotinylated cells were washed twice in PBS pH 7.4, centrifuged
to collect, and lysed in 1% Triton X-100 lysis buffer (1% Triton,
10 mM Tris-HCL, 150 mM NaCl, cOmplete protease inhibitor,
5 mM IAA) for 30 min on ice. Nuclei were removed byFrontiers in Immunology | www.frontiersin.org 3centrifugation at 4°C, 13,000 g, 5 min, and this was repeated
three times. Biotinylated glycoproteins were enriched with high
affinity streptavidin agarose beads (Thermo) and washed
extensively using a vacuum manifold and Poly-Prep columns
(BioRad). Washing was initially with lysis buffer, then 0.5% SDS
and then urea. Captured protein was reduced with DTT,
alkylated with iodoacetamide (IAA, Sigma) and digested on-
bead with trypsin (Promega) in 100 mM HEPES pH 8.5 for 3h.
Tryptic peptides were collected. A prior study determined that
biotinylation under identical conditions was confined to the cell
surface, with no discernable labeling of either endosomes or
lysosomes (31).
Peptide Labeling With Tandem Mass Tags
TMT reagents (0.8mg) were dissolved in 43 µl of anhydrous
acetonitrile, and 5 µl was added to the peptide samples at a final
concentration of 30% acetonitrile (v/v). Following incubation for
1 h at room temperature, the reaction was quenched with
hydroxylamine to a final concentration of 0.05% (v/v). TMT
labeled samples were combined 1:1 (THP-1 cells) and 1:1:1:1
(pan-monocytes), vacuum centrifuged to near dryness and then
desalted using a StageTip (32) before analyzing a small fraction
of the sample in a ‘single shot’ by LC-MS3.
For primary monocytes and CD4+ T cells, a small amount of
each sample was initially labeled and combined 1:1:1:1:1:1:1:1:1:1
for a single shot, as described above. The remainder of the sample
was then labeled and the amounts combined were adjusted to
ensure equal loading of peptide from each sample, to avoid a
requirement for excessive digital normalization. Samples were
not quenched until adequate labeling had been confirmed by
analysis of a single shot on the mass spectrometer, in some cases
necessitating addition of more TMT reagent. For CD4+ T cells,
single shot analysis was initially of stimulated and unstimulated
samples derived from three donors, which was later extended to a
10-plex analysis on addition of samples from two further donors.
Following single shot analysis of primary CD14+ monocytes and
CD4+ T cells, TMT-labeled and combined samples were subject
to C18 solid phase extraction (Sep-Pak, Waters) and SCX
fractionation (see below) resulting in six fractions, in order to
increase the overall number of peptides quantified. Each fraction
was then desalted using a StageTip prior to analysis by LC-MS3.
Details of individual sample labeling, and mass spectrometry
analyses are described in Table S5.
Offline Tip-Based Strong Cation Exchange
SCX Fractionation
A protocol for solid-phase extraction based SCX peptide
fractionation was previously modified for small peptide
amounts (28). Briefly, 10 mg of PolySulfethyl A bulk material
(Nest Group Inc) was loaded on to a fritted 200 µl tip in 100%
Acetonitrile using a vacuum manifold. The SCX material was
conditioned slowly with 2x 400 µl SCX buffer A (7mM KH2PO4,
pH 2.65, 30% Acetonitrile), 400 µl SCX buffer B (7mM KH2PO4,
pH 2.65, 350mM KCl, 30% Acetonitrile) and then 4x 400 µl SCX
buffer A. Dried peptides were resuspended in 400 µl SCX buffer
A and added to the tip under vacuum, with a flow rate of ~150 µl/
min. The tip was then washed with 150 µl SCX buffer A.February 2021 | Volume 12 | Article 600056
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increasing K+ concentrations (10, 25, 40, 60, 90, 150mM KCl),
vacuum-centrifuged to near dryness then desalted using StageTips.
LC-MS3
Mass spectrometry data was acquired using an Orbitrap Fusion
for all experiments apart from the two initial CD14+ monocyte
single shots and the 10-plex CD4 single shot, where an Orbitrap
Fusion Lumos was used instead (Thermo Fisher Scientific, San
Jose, CA), as detailed in Table S5B. In both cases, an Ultimate
3000 RSLC nano UHPLC equipped with a 300 µm ID x 5 mm
Acclaim PepMap µ-Precolumn (Thermo Fisher Scientific) and a
75 µm ID x 50 cm 2.1 µm particle Acclaim PepMap RSLC
analytical column was used.
For Orbitrap Fusion Lumos experiments: Loading solvent was
0.1% FA, analytical solvent A: 0.1% FA and B: 80%MeCN + 0.1%
FA. Separations were carried out at 40°C (gradient 1) or 55°C
(gradient 2 and 3). Samples were loaded at 5 µl/min for 5 min in
loading solvent before beginning the analytical gradient. The
following gradients were used. Gradient 1: 3%–40% B over 55
min, followed by a 5 min wash at 95% B and equilibration at 3%
B for 10 min. Gradient 2: 3%–7% B over 3 min, 7%–37% over 54
min followed by 2 min wash at 95% B and equilibration at 3% B
for 15 min. Gradient 3: 3%–7% B over 3 min, 7%–37% B over 176
min followed by a 4 min wash at 95% B and equilibration at 3% B
for 15 min. Each analysis used a MultiNotch MS3-based TMT
method (33). The following settings were used: MS1: 380–1,500
Th, 120,000 Resolution, 2x105 automatic gain control (AGC)
target, 50 ms maximum injection time. MS2: Quadrupole
isolation at an isolation width of m/z 0.7, CID fragmentation
(normalized collision energy (NCE) 35) with ion trap scanning
in turbo mode from m/z 120, 1x104 AGC target and 50 ms
maximum injection time for gradient 1 or 1.5x104 AGC target
and 120 ms maximum injection time for gradients 2 and 3. MS3:
In Synchronous Precursor Selection mode the top 10 MS2 ions
were selected for HCD fragmentation (NCE 65) and scanned in
the Orbitrap at 60,000 resolution with an AGC target of 1x105
and a maximum accumulation time of 120 ms for gradient 1 or
150 ms for gradients 2 and 3. Ions were not accumulated for all
parallelisable time. The entire MS/MS/MS cycle had a target time
of 3 s. Dynamic exclusion was set to +/− 10 ppm for 70 s. MS2
fragmentation was trigged on precursors 5x103 counts
and above.
For Orbitrap Fusion experiments: Loading solvent was 0.1%
TFA, analytical solvent A: 0.1% FA and B: MeCN + 0.1% FA. All
separations were carried out at 55°C. Samples were loaded at 10
µl/min for 5 min in loading solvent before beginning the
analytical gradient. All samples were run with a gradient of
3%–34% B, followed by a 5 min wash at 80% B, a 5 min wash at
90% B and equilibration at 3% B for 5 min, resulting in a total
gradient over the time indicated in Table S5B. Each analysis used
a MultiNotch MS3-based TMT method (33). The following
settings were used: MS1: 400-1400 Th, Quadrupole isolation,
120,000 Resolution, 2x105 AGC target, 50 ms maximum
injection time, ions injected for all parallizable time. MS2:
Quadrupole isolation at an isolation width of m/z 0.7, CIDFrontiers in Immunology | www.frontiersin.org 4fragmentation (NCE 30) with ion trap scanning out in rapid
mode from m/z 120, 1x104 AGC target, 70 ms maximum
injection time, ions accumulated for all parallizable time in
centroid mode. MS3: in Synchronous Precursor Selection mode
the top 10 MS2 ions were selected for HCD fragmentation (NCE
65) and scanned in the Orbitrap at 50,000 resolution with an
AGC target of 5x104 and a maximum accumulation time of 150
ms, ions were not accumulated for all parallelisable time. The
entire MS/MS/MS cycle had a target time of 3 s. Dynamic
exclusion was set to +/- 10 ppm for 90 s. MS2 fragmentation
was trigged on precursors 5x103 counts and above.
Quantification and Statistical Analysis
Data Analysis
Mass spectra were processed using a Sequest-based software
pipeline for quantitative proteomics, “MassPike”, through a
collaborative arrangement with Professor Steve Gygi’s
laboratory at Harvard Medical School. MS spectra were
converted to mzXML using an extractor built upon Thermo
Fisher’s RAW File Reader library (version 4.0.26). In this
extractor, the standard mzxml format has been augmented
with additional custom fields that are specific to ion trap and
Orbitrap mass spectrometry and essential for TMT quantitation.
These additional fields include ion injection times for each scan,
Fourier Transform-derived baseline and noise values calculated
for every Orbitrap scan, isolation widths for each scan type, scan
event numbers, and elapsed scan times. This software is a
component of the MassPike software platform and is licensed
by Harvard Medical School.
The human UniProt database (26th January, 2017), was
combined with a database of common contaminants such as
porcine trypsin. The combined database was concatenated with a
reverse database composed of all protein sequences in reversed
order. Searches were performed using a 20 ppm precursor ion
tolerance (34). Product ion tolerance was set to 0.03 Th. TMT
tags on lysine residues and peptide N termini (229.162932 Da)
and carbamidomethylation of cysteine residues (57.02146 Da)
were set as static modifications, while oxidation of methionine
residues (15.99492 Da) was set as a variable modification.
To control the fraction of erroneous protein identifications, a
target-decoy strategy was employed (35, 36). Peptide spectral
matches (PSMs) were filtered to an initial peptide-level false
discovery rate (FDR) of 1% with subsequent filtering to attain a
final protein-level FDR of 1% (37, 38). PSM filtering was
performed using a linear discriminant analysis, as described
(39). This distinguishes correct from incorrect peptide IDs in a
manner analogous to the widely used Percolator algorithm (40),
though employing a distinct machine learning algorithm. The
following parameters were considered: XCorr, DCn, missed
cleavages, peptide length, charge state, and precursor mass
accuracy. Protein assembly was guided by principles of
parsimony to produce the smallest set of proteins necessary to
account for all observed peptides (39).
Proteins were quantified by summing TMT reporter ion
counts across all matching peptide-spectral matches using
“MassPike”, as described (33, 41). A minimum of one uniqueFebruary 2021 | Volume 12 | Article 600056
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0.003 Th window around the theoretical m/z of each reporter ion
(126, 127n, 127c, 128n, 128c, 129n, 129c, 130n, 130c, 131n) was
scanned for ions, and the maximum intensity nearest to the
theoretical m/z was used. The primary determinant of
quantitation quality is the number of TMT reporter ions detected
in eachMS3 spectrum, which is directly proportional to the signal-
to-noise (S:N) ratio observed for each ion (42). Conservatively,
every individual peptide used for quantitation was required
to contribute sufficient TMT reporter ions so that each on its own
could be expected to provide a representative picture of relative
protein abundance (41). Additionally, an isolation specificity filter
with a cut-off of 50% was employed to minimize peptide co-
isolation (43). Peptide-spectral matches with poor quality MS3
spectra (more than 9 TMT channels missing and/or a combined S:
N ratio of less than 25 for each channel used (as detailed in Table
S5B) or no MS3 spectra at all were excluded from quantitation.
Peptides meeting the stated criteria for reliable quantitation
were then summed by parent protein, in effect weighting the
contributions of individual peptides to the total protein signal
based on their individual TMT reporter ion yields. Protein
quantitation values were exported for further analysis in Excel.
For protein quantitation, reverse and contaminant proteins
were removed, then each reporter ion channel was summed
across all quantified proteins and normalized assuming equal
protein loading across all channels. For all TMT experiments,
normalized S:N values are presented in Table S1 (‘Data’
worksheet). Proteins were defined as being PM proteins, and
used in further analysis if they had a GO annotation of “plasma
membrane”, “cell surface”, “extracellular” or “short GO” (29). All
analysis was performed following filtering of the data to include
only proteins that had relevant gene ontology annotations.
As there are challenges in confidently assigning peptides to a
specific HLA allele, and to account for different alleles being
expressed in the different donors, the S:N values were summed to
give a single value for HLA-A, HLA-B, HLA-C and HLA-DRB1.
Additionally, all classical HLA molecules were excluded from the
investigation of cell surface protein abundance (Figure 2, Figure
S2A, and Table S3). Furthermore, data for proteins quantified in
<3 donors following subsequent filtering (NOX4, GYPA, JAK3
and SLC25A3) was removed prior to analysis.
To estimate the relative abundance of each protein, a method
based on iBAQ was employed. The summed MS1 maximum
precursor intensity for each protein across all matching peptides
was calculated. Each value was divided by the number of
theoretically observable tryptic peptides 7–30 amino acids in
length for the respective protein, as determined by in silico
trypsin digestion of human Swissprot canonical and isoform
database (2017_01_26) using the OrgMassSpecR51 package in R
3.5.152. To determine the abundance of a protein at the surface of
unstimulated cells, the summed intensity was adjusted in
proportion to normalized S:N values: (Donor 1 + Donor 2 +
Donor 3 + Donor 4 + Donor 5 unstimulated)/∑(all donors ± IFN)
(Figure 2). To compare donors, the intensity was adjusted in
proportion to the unstimulated sample for that donor (eg Donor
1 unstimulated/∑(all donors ± IFN) (Figure S2A).Frontiers in Immunology | www.frontiersin.org 5To prevent overestimation of the IFN-induced fold change
(FC), individual donor FCs derived from S:N values that
contributed < 2% of the total S:N in either the IFNa2a
stimulated or unstimulated sample were excluded. Proteins
were only considered to be consistently upregulated if the fold
change was >1 for every donor in which the protein was
quantified, and <1 in every donor for downregulation.
Statistical Analysis
Figure 2C. The percent of the cell surface contributed by each
protein in monocytes and T cells was compared. The ratios were
log2 transformed, and the mean and SD across all 280 proteins
calculated, in order to determine which proteins changed > 1, 2,
or 3 SD from the mean protein fold change.
Figure 3 and Figure S3. P-values were calculated in Excel
using a paired, two-tailed Student’s t-test on log-transformed
data, then subjected to Benjamini-Hochberg multiple testing
correction (44). The color of the average fold change bar was
determined by log2 transforming the data and determining the
number of standard deviations the FC for a given protein was
away from the mean FC for all proteins, as indicated in
the legend.
Figure S1. P values were estimated using significance B (45),
calculated using Perseus version 1.5.4.1 (46).
Figure S2. r2 values were calculated using Excel.
Data Availability
The mass spectrometry proteomics data have been deposited to the
ProteomeXchangeConsortium(http://www.proteomexchange.org/)
via the PRIDE (47) partner repository with the dataset identifier
PXD022834. All materials described in this manuscript, and any
furtherdetails ofprotocols employedcanbeobtainedonrequest from
the corresponding author by email to mpw1001@cam.ac.uk.
Cell Surface Flow Cytometry
Cells were washed in FACS buffer (PBS with 2% FBS), prior to
blocking in Human Trustain (Biolegend, 422302, 1:20 in FACS
buffer) for 10 min at room temperature. Samples shown in
Figure S7 were additionally blocked with mouse serum (1:50).
All stainswereperformed for 30minat 4°C,with antibodies diluted
in FACS buffer: anti-CD14-PE (Biolegend, 301850, 1:20, RRID:
AB_2564138), anti-CD4-APC (Biolegend, 317415, 1:20, RRID:
AB_571944), anti-CD3-FITC (Biolegend, 300406, 1:20,
RRID: AB_314060), anti-IFNAR2-APC (Miltenyi, 130-099-560,
1:20,RRID:AB_2652223), anti-BST2-PE (Biolegend, 348405, 1:20,
RRID: AB_10567247), anti-CD69-PE (Biolegend, 310905, 1:20,
RRID: AB_314840), anti-CD38-PE (Biolegend, 356603,
1:20, AB_2561899), anti-CD40-PE (Biolegend, 334307, 1:20,
RRID: AB_1186060), anti-SIGLEC1-APC (Biolegend, 346007,
1:20, RRID: AB_11150773), anti-CD274-PE (Biolegend, 329705,
1:20, RRID: AB_940366), anti-NRP1-PE (Biolegend, 354503, 1:20,
RRID: AB_11219200), and anti-SLAMF7 (Santa Cruz, sc-53577,
1:50, RRID: AB_1121905). For the sample incubated with
unconjugated anti-SLAMF7, secondary staining employed either
anti-mouse-AF647 (Figure 5C, Invitrogen, A21236, 1:1,000,
RRID: AB_141725) or anti-mouse-AF488 (Figure S7B, CST,February 2021 | Volume 12 | Article 600056
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were fixed with 4% paraformaldehyde (Biolegend) for 10 min at
room temperature, before being analyzed on a Becton-Dickinson
FACSCalibur, Becton Dickinson LSR Fortessa or Becton
DickinsonAccuriC6.Datawas analyzed usingFlowJo vX software.
Immunoblotting
Preparation of Cell Lysates for Immunoblot
For whole cell protein analysis, cells were lysed in RIPA buffer
(Cell Signaling Technology) containing cOmplete Mini Protease
Inhibitor Cocktail (Roche) for 15–30 min at 4°C prior to
clarifying by centrifugation at 14,000g for 10 min.
For preparation of samples enriched in PM proteins, cells
were stimulated overnight with IFN, then biotinylated and lysed
as described for proteomics. PM proteins were enriched by
incubation with streptavidin beads for 2 h, followed by washes
with lysis buffer and 0.5% SDS. The streptavidin beads were
resuspended in SDS page buffer, boiled at 95°C for 10 min and
the supernatant collected prior to immunoblot analysis.
Immunoblot
Protein concentration was measured using a BCA assay (Pierce)
according to the manufacturer’s instructions. Samples were
denatured and reduced with 6× protein loading dye (375 mM
Tris pH 6.8, 12% SDS, 30% glycerol, 0.6 M DTT, 0.06%
bromophenol blue) for 5 min at 95°C. 50 µg of protein was
separated by SDS polyacrylamide gel electrophoresis (PAGE)
using Mini-PROTEAN TGX precast gels (Bio-Rad, 456-1085),
then transferred to polyvinylidene difluoride (PVDF)
membranes (0.45 µm pore) using the Bio-Rad wet (Figures 5E,
H and Figure S5) or semi-dry (Figure 5G) transfer system. The
membrane was blocked with 5% milk in TBST before probing
overnight at 4˚C with anti-GAPDH (R&D Systems, MAB5718,
1:10,000, RRID: AB_10892505) and anti-ECE1 (Abcam,
ab71829, 1:1,000, RRID: AB_2277809) or anti-phospho-STAT1
(Cell Signaling Technology, 9167S, RRID: AB_561284).
Secondary antibodies used were IRDye 680RD goat anti-mouse
(LI-COR, 925-68070, 1:10,000, RRID: AB_2651128) and IRDye
800CW goat anti-rabbit (LI-COR, 925-32211, 1:10,000, RRID:
AB_2651127). Fluorescent signals were detected using a LI-COR
Odyssey CLx, and images were processed using Image Studio
Lite version 5.2 (LI-COR).
Revert 700 Total Protein Stain kit (LI-COR) was used to
quantify the total abundance of proteins in each of the plasma
membrane enriched samples in order to normalize ECE1 signal
between unstimulated and IFNa2a-stimulated conditions
(Figure 5H), according to the manufacturer’s instructions.
RT-qPCR
Total RNA was extracted using an RNeasy Mini Kit (Qiagen),
followed by removal of contaminating DNA using the TURBO
DNA-free reagents (Invitrogen) and cDNA synthesis using
GoScript Reverse Transcriptase kit (Promega), following the
manufacturer’s instructions. RT-qPCR was performed using
the TaqMan gene expression master mix (Applied Biosystems)
w i t h Taqman p rob e s (The rmoF i s h e r ) f o r ECE1Frontiers in Immunology | www.frontiersin.org 6(Hs01043735_m1), TMEM123 (Hs00920881_m1), and
GAPDH (Hs02786624_g1). Analysis was performed on the
7500 Fast & 7500 real-time PCR systems (Applied Biosystems).
The PCR program consisted of activation at 95°C for 2 min,
followed by 40 cycles of denaturation at 95°C for 5 s and
annealing/extension at 60°C for 30 s.RESULTS
Validation of the Workflow in THP-1 Cells
To establish a robust protocol for cellular stimulation with
IFNa2a followed by PM protein isolation, we first examined
the cultured monocytic cell line THP-1. Cells were cultured
overnight in the presence or absence of 1,000 IU/ml IFNa2a then
subjected to PM profiling (27, 28). Of 570 proteins with a gene
ontology (GO) annotation of “plasma membrane”, “cell surface”,
“extracellular” or “short GO” (29), 31 were upregulated >1.5 fold
(Figure S1, Table S1). These included multiple class I major
histocompatibility complex (MHC) molecules, the IFN
stimulated HIV restriction factor tetherin (Bone Marrow
Stromal Cell Antigen 2, BST2), and the receptor tyrosine
kinase AXL, all of which are known positive controls (48, 49).
A smaller subset of 13 proteins were downregulated >1.5 fold,
including the Interferon alpha/beta receptor 1 (IFNAR1)
component of the IFN receptor, as has also been previously
reported (50).
Quantitative Comparison of the Cell
Surface Proteome of Primary CD14+
Monocytes and CD4+ T Cells
To quantify IFNa-stimulated changes in primary leukocytes,
peripheral blood mononuclear cells (PBMCs) were isolated from
ten donors. Negative selection was used to enrich CD14+
monocytes from five donations, and CD4+ T cells from
another five donations. Flow cytometry confirmed that the
purity of each population was ≥90% (Table S2A). Aliquots of
cells from each donation were then either stimulated overnight
with IFNa2a or left unstimulated, followed by isolation and
quantitation of PM proteins (Figure 1). Overall 606 annotated
PM proteins were quantified in CD14+ monocytes and 482 in
CD4+ T cells (Table S2B). All data are shown in Table S1, in
which the interactive “Plotter” worksheet displays results for
each protein of interest.
In addition to enabling quantitation of IFNa-stimulated
changes in PM proteins, this data facilitated comparison of the
cell surface proteome between the different cell types, using a
method based on intensity based absolute quantification (iBAQ
(25)). Remarkably, 17 proteins contributed more than 1% each to
the cell surface proteome of unstimulated CD14+ monocytes,
with the summed contribution from all 17 totalling ~75%
(Figure 2A, Table S3A). In fact, the five most abundant
proteins composed ~57% of the surface proteome: CD44,
solute carrier family 2 facilitated glucose transporter member 3
(SLC2A3), leukosialin (SPN), basigin (BSG) and Protein
Tyrosine Phosphatase Receptor Type C (PTPRC). Similarly, inFebruary 2021 | Volume 12 | Article 600056
Soday et al. IFNa Modulated Leukocyte Surface ProteomeFIGURE 1 | Schematic of experimental workflow for plasma membrane proteomic analysis of IFNa2a-stimulated and unstimulated primary CD14+ monocytes or
CD4+ T cells. For each cell type, five independent donations were cultured overnight in the presence or absence of IFNa2a, before selective oxidation and
aminooxy-biotinylation of cell surface glycoproteins. Proteins were enriched on streptavidin beads, digested with trypsin, and peptides from each of the 10 samples
labeled with tandem mass tag (TMT) reagents then subjected to MS3 mass spectrometry.A B
C
FIGURE 2 | Proteomic cell surface map of primary CD14+ monocytes and CD4+ T cells. (A) Pie chart of the relative contribution of individual proteins to the plasma
membrane (PM) proteome of unstimulated primary CD14+ monocytes. iBAQ abundance values for each protein were estimated from the sum of the maximum
precursor intensity for all contributing peptides divided by the theoretical number of tryptic peptides between 7–30 amino acids in length. The value was scaled
according to the signal detected in the five unstimulated samples compared to the total signal in all ten IFN-stimulated and unstimulated samples, to give an estimate
of the protein expression at the surface of unstimulated cells. Classical class I and II MHC molecules were excluded from all iBAQ analyses to eliminate bias
introduced by differentially expressed alleles between different donors. Proteins contributing less than one percent are grouped into ‘other’. The complete dataset is
given in Tables S1 and S3A. (B) Pie chart of the relative contribution of individual proteins to the PM proteome of unstimulated primary CD4+ T cells, calculated and
displayed as described in (A). The complete dataset is given in Tables S1 and S3B. (C) Comparison of the contribution of 280 proteins to the PM proteome of
unstimulated primary CD14+ monocytes and CD4+ T cells. Classical class I and II MHC molecules were excluded as described in (A). Color coding illustrates the
number of standard deviations (SD) from the mean for each protein’s log2 ratio (% PM proteome (CD14+ monocytes)/% PM proteome (CD4+ T cells)). The complete
dataset is given in Tables S1 and S3C.Frontiers in Immunology | www.frontiersin.org February 2021 | Volume 12 | Article 6000567
Soday et al. IFNa Modulated Leukocyte Surface ProteomeCD4+ T cells, 22 proteins contributed more than 1% of the cell
surface proteome, with the summed contribution from all 22
totalling ~67% (Figure 2B, Table S3B).
The abundance of 280 PM proteins quantified in both CD4+ T
cells and CD14+ monocytes generally correlated well, with CD44,
SPN (CD43) and PTPRC (CD45) among the five most abundant
proteins in both cell types (Figure 2C, Table S3C). All three
molecules have roles in cell adhesion and/or cellular activation (51–
54). Expression of other proteins was more cell-type specific.
For example, the myeloid-lineage membrane receptor signal
regulatory protein alpha (SIRPA) was ~32-fold more abundant on
CD14+ monocytes than CD4+ T cells, and the scavenger receptor
cysteine-rich superfamily member CD5 was >100 fold more
abundant on CD4+ T cells than CD14+ monocytes. SLC2A3 (also
known as glucose transporter GLUT-3), was previously found to be
8.4 times more abundant in monocytes compared to lymphocytes,
while GLUT1 (SLC2A1) wasmore abundant in lymphocytes (55), in
keeping with the data presented here (Table S3C).
The use of multiplexed proteomics also enabled the
assessment of donor-to-donor variation in protein expression
in unstimulated cells. Both CD14+ monocytes and CD4+ T cells
revealed remarkably invariant cell surface proteomes, with a
strong positive correlation observed for all pairwise comparisons
(Figure S2A, Tables S3A, B).
IFNa2a-Stimulated Cell Surface Changes
in CD14+ Monocytes
In primary CD14+monocytes, 57 proteins were upregulated by >1
SD above the mean protein fold change (FC), of which 41/57
(72%) were consistently upregulated (FC>1) for all donors in
which they were quantified (Figure 3A, Figure S3 and Tables
S4A, B). For 21/41 (51%) of these proteins the difference between
protein expression in stimulated and unstimulated samples was
significant at p < 0.05 (paired two-tailed Student’s t-test, corrected
for multiple hypothesis testing using the method of Benjamini-
Hochberg (44)). These included several factors well known to
exhibit IFNa2a stimulation such as BST2, multiple HLA
molecules, and the ubiquitin-like protein ISG15 (56).
Extracellular proteins bound to the plasma membrane such as
ISG15 were routinely quantified in our plasma membrane
preparations. Using the same criteria, 55 proteins were
consistently downregulated in CD14+ monocytes, of which 30
exhibited significance with p<0.05 (Figure 3B and Tables S4A, C).
To validate these findings in independently derived samples,
whole monocyte cell populations were enriched from two further
donors using a ‘pan-monocyte’ Dynabead enrichment kit. 81% of
proteins consistently upregulated by IFNa in CD14+ monocytes
were also consistently upregulated in the whole monocyte
populations by the same criteria, providing confidence in our data
(Figure S4A). Many of the proteins most substantially
downregulated by IFNa2a in the CD14+ monocytes were
similarly downregulated in the whole monocyte population
(Figure S4A, Table S4D).
Finally, comparison of the CD14+monocyte data to the THP-1
sample identified 357 PM proteins commonly quantified. Twenty-
eight proteins were upregulated and 40 downregulated in primaryFrontiers in Immunology | www.frontiersin.org 8CD14+ monocytes (according to criteria detailed above), whereas
36 were upregulated and 18 downregulated in THP-1s. Of these
proteins, 16 were commonly upregulated and six commonly
downregulated in both cell types (Figure S4B, Table S4E).
Characterizing the similarities and differences between these cell
types is important for evaluating the potential of THP-1s as a
model for primary cells.
IFNa2a-Stimulated Cell Surface Changes
in CD4+ T Cells
Applying the same filtering criteria used for analysis of monocyte
populations, only 13 proteins were consistently up-regulated and
14 proteins consistently down-regulated in primary CD4+ T cells
(Figure 3C and Tables S4A, F, G). None of these changes were
statistically significant, despite consistent regulation among all
five donors. This may reflect heterogeneity in populations of
CD4+ T cells from different donors, or over-stringency of the
multiple testing correction in the context of proteomic data (57).
Nevertheless, identification of positive controls again provided
confidence in the data, including consistent IFNa2a-stimulated
upregulation of multiple HLA molecules and BST2. The IL-1
receptor antagonist (IL1RN) is known to be regulated by IFNa
with roles in modulating the inflammatory response (58, 59), and
C-type natriuretic peptide (CNP) is a known ISG involved in
inhibiting HIV particle assembly (60). Additionally, the IL-6
receptor (IL6R) was downregulated by IFNa, as has been
previously been reported (61).
Comparison of IFNa2a-Stimulated
Proteins in Monocytes and T Cells
Expression of the IFNAR1 chain of the IFN receptor was
detected in monocytes by proteomics (Table S1), and
expression of IFNAR2 was confirmed in both primary
monocytes and T cells by cell surface flow cytometry (Figure
S5A). Phosphorylation of STAT1 upon IFN stimulation was
confirmed in both cell types by immunoblot (Figure S5B).
However, IFN responses are known to be cell type specific (6,
7). Of the 284 proteins quantified in both CD14+ monocytes and
CD4+ T cells, five were IFNa2a-stimulated in both cell types
(Figure 4). These included the known HIV restriction factor
BST2, HLA-C, E and F, and Transmembrane Protein 123
(TMEM123). TMEM123 was also stimulated by IFNa2a in
samples from both pan-monocyte donors, and in THP-1 cells
(Figure S4). In contrast, four proteins were only stimulated by
IFNa2a in CD4+ T cells including Endothelin Converting
Enzyme-1 (ECE1). 11 proteins were only IFNa2a-stimulated in
CD14+ monocytes including ADP-Ribosyl Cyclase 1 (CD38)
(Figure 4, Table S4H). These findings were consistent with the
greater breadth of protein changes in CD14+ monocytes
compared to CD4+ T cells (Figure 3). In keeping with these
observations, a previous transcriptomic study demonstrated that
in the context of TNFa pre-treatment, subsequent IFNb
treatment stimulated many more transcripts in monocytes
than in T cells (667 monocyte-specific transcripts compared to
21 T cell-specific transcripts) (62). Additionally, combined data
from multiple transcriptomic studies of primary and culturedFebruary 2021 | Volume 12 | Article 600056
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FIGURE 3 | IFNa2a-induced changes at the PM of CD14+ monocytes and CD4+ T cells. (A) Proteins consistently upregulated by IFNa2a in primary CD14+
monocytes (FC > 1SD from the mean, with FC > 1 in all donors). Dots display the fold change for each donor, and the line represents average FC. Data for all
proteins upregulated >1 SD above the mean, prior to filtering for consistent upregulation is shown in Figure S3. A Benjamini-Hochberg-corrected paired, two-tailed
t-test was used to estimate the p-value that each protein exhibited significant change in expression upon IFNa stimulation (*p<0.05). The complete dataset is given in
Tables S1 and S4B. (B) Proteins consistently downregulated by IFNa2a stimulation in primary monocytes, determined as in (A) (FC > 1SD from the mean, and
FC<1 in all donors). The complete dataset is given in Tables S1 and S4C. (C) Proteins consistently up- or downregulated in primary CD4+ T cells, as described in
(A, B). The complete dataset is given in Tables S1 and S4F, G.Frontiers in Immunology | www.frontiersin.org February 2021 | Volume 12 | Article 6000569
Soday et al. IFNa Modulated Leukocyte Surface Proteomecells stimulated with type I IFNs demonstrated 567 ISGs
changing in abundance upon IFN stimulation for monocytes
compared to 124 for T cells (7).
Donor-to-Donor Variation in IFNa2a–
Stimulated Changes in the PM Proteome
In contrast to a relative invariance in the cell surface proteome
between different donors (Figure S2A), there was a greater degree
of donor-to-donor variation in IFNa2a-induced changes in the
PM proteome, particularly for CD4+ T cells (Figure S2B). While
just 13 proteins met criteria for consistent upregulation in T cells,
112 proteins were upregulated more than 1.5 fold in at least one
donor. Importantly, this variation did not result from a
systematically greater IFNa2a effect in some donors than other,
as the pattern of induced FCs appeared random (Figure S6).
Validation of IFNa2a-Stimulated Changes
A subset of proteins modulated by IFNa2a in primary CD14+
monocytes were selected for validation in three donors using flow
cytometry (Figures 5A–C and Figure S7). ECE1 was the most
substantially IFNa2a-stimulated cell surface protein in all five
donors in primary CD4+ T cells (Figure 3C). This change was
validated at the level of whole cell proteins and transcript (Figures
5D–G). Furthermore, stimulation of ECE1 at the cell surface of
Jurkat T cells was demonstrated by immunoprecipitation of
biotinylated cell surface proteins and immunoblot (Figure 5H).
Apart from BST2 and HLA molecules, TMEM123 was the only
protein upregulated in both monocytes and T cells (Figure 4).
Stimulation of TMEM123 transcript in THP-1 cells by IFNa2a was
validated (Figures 5I, J). However, despite testing four
commercially available antibodies for TMEM123 by immunoblotFrontiers in Immunology | www.frontiersin.org 10and flow cytometry in cells depleted of TMEM123 by RNAi or
overexpressing TMEM123, we were unable to identify any reagent
that exhibited specific binding to TMEM123 protein meaning that
validation at the protein level was not possible.DISCUSSION
This study represents the first systematic analysis of the effects of
type I IFN at the cell surface, and the most comprehensive
analysis of the surface proteome of primary monocytes and
CD4+ T cells to date. 606 and 482 annotated cell surface
proteins were quantified in primary CD14+ monocytes and
CD4+ T cells respectively. For comparison, only 229 proteins
were previously identified at the surface of CD4+ T cells by a
combination of proteomics and flow cytometry, and 274 proteins
from CD4+CD25- cells by proteomics (63, 64). Furthermore, the
use of TMT technology enabled multiplexing of samples in order
to investigate samples from five donors in parallel, allowing
direct investigation of donor-to-donor variation in protein
abundance, identification of consistent IFNa2a-stimulated
effects and quantitation of cellular responses to IFNa2a.
Whereas just 13 proteins were consistently upregulated by
IFNa2a at the PM of CD4+ T cells, 41 were upregulated in CD14+
monocytes. Some of these proteins are maturation markers of
monocyte-derived DCs, including CD83 (65), CD38 (66), the co-
stimulatory molecule CD86, C-C Chemokine Receptor Type 7
(CCR7) and HLA-DR (67). Mature DCs are routinely generated in
vitro by treatment of monocytes with GM-CSF, IL-4 and TNFa. In
a previous comparative microarray analysis, GM-CSF/IL-4/TNFa
derived DCs expressed higher levels of transcripts involved inFIGURE 4 | Comparison of the effects of IFNa2a on the plasma membrane (PM) proteome of primary CD14+ monocytes and CD4+ T cells. Comparison of data for
284 proteins quantified in both CD14+ monocytes and CD4+ T cells. These 284 proteins include 280 proteins described in Figure 2C and additionally classical
class I and class II HLA molecules. Proteins are defined as modulated by IFNa2a according to the previously defined criteria (FC > 1SD from the mean, and FC > 1
in all donors for upregulation, FC < 1 in all donors for downregulation). Full data is shown in Tables S1 and S4H. Certain proteins including ISG15 did not meet cut-
offs for upregulation by IFNa2a in CD4+ T cells due to inconsistent upregulation across donors (Table S1).February 2021 | Volume 12 | Article 600056
Soday et al. IFNa Modulated Leukocyte Surface Proteomephagocytosis and adhesion, whereas DCs generated by stimulation
with GM-CSF and IFNa expressed greater levels of transcripts
associated with migration (68). CD86, HLA-DR, and CCR7
transcripts were upregulated in GM-CSF/IFNa-generated DCs,
consistent with our observations. Similarly, a limited flow
cytometry-based study of IFNa stimulation identifiedFrontiers in Immunology | www.frontiersin.org 11upregulation of CD86, CD83 and CCR7 in monocyte and whole
PBMC populations (69). Our study thus suggests that stimulation
with IFNa2a alone may be sufficient to induce a degree of
monocyte differentiation, and that cellular differentiation may
explain the broader cell surface regulation of a subset of the
proteins modulated by IFNa2a.A B





FIGURE 5 | Validation of proteomic data. (A) Proteomic quantitation of a subset of proteins stimulated by IFNa2a in primary CD14+ monocytes. Each point
represents a single donor. Data is a subset of that shown in Figure 3A, and Table S1. (B) Flow cytometry-based validation of IFNa2a-stimulated change in BST2
expression at the surface of primary CD14+ monocytes (top) and CD4+ T cells (bottom). Similar data from an additional donor is shown in Figure S7A. (C)
Validation by flow cytometry of a selection of proteins stimulated by IFNa2a in primary CD14+ monocytes. Early activation antigen CD69, CD38, CD40, sialoadhesin
SIGLEC1 and programmed cell death 1 ligand 1 (CD274) were quantified in CD14+ monocytes from one donor, while SLAMF7 was quantified in cells donated by a
second individual. Red (unstimulated) and blue (stimulated with IFNa2a) coloring as in Figure 5B. For SLAMF7 staining, the gray line represents a control sample
stained only with secondary antibody (anti-mouse-AF647). For all other samples, the gray line represents unstained samples as directly conjugated antibodies were
employed. Similar data from two additional donors is shown in Figures S7B, (C). (D) Proteomic quantitation of cell surface ECE1 in different cell types. Full data is
given in Table S1. (E) ECE1 protein is upregulated in the whole cell protein lysate from IFNa2a-stimulated primary CD4+ T cells. Data is from a single donor.
(F) qPCR confirming IFNa2a-stimulated upregulation of ECE1 in primary CD4+ T cells, at the level of mRNA (Data is from a single donor, with three technical
replicates). (G) Immunoblot confirming IFNa2a-stimulated upregulation of ECE1 in whole cell protein lysates from two cultured T cell lines Jurkats and SUPT1s (n=1).
(H) Immunoblot after immunoprecipitation (IP) of biotinylated cell surface proteins confirming IFNa2a-stimulated upregulation of ECE1 at the cell surface of Jurkat T
cells. ‘Whole cell input’ represents protein lysates prior to PM enrichment, and ‘PM IP’ represents PM-enriched samples. For the quantitation shown in the bar chart
below the immunoblot, signals from the ECE1 bands following immunoprecipitation were normalized according to the relative amounts of PM protein loaded on both
lanes of the gel. This was measured using a total protein stain and quantified using Image Studio Lite (n=1). (I) Proteomic quantitation of cell surface TMEM123,
demonstrating upregulation by IFNa2a in all cell types. Full data is given in Table S1. (J) TMEM123 upregulation by IFNa2a was validated in THP-1s by qPCR (three
technical replicates).February 2021 | Volume 12 | Article 600056
Soday et al. IFNa Modulated Leukocyte Surface ProteomeA particularly interesting use of our data may be the
identification of novel cell surface antiviral restriction factors, on
the basis of both stimulation by IFN and targeting for degradation
by a viral factor (5). For example, BST2 (tetherin) was upregulated
by IFNa2a onCD14+monocytes andCD4+T cells. BST2 has been
extensively characterized for its ability to inhibit replication of HIV
in addition to flaviviruses, herpesviruses, rhabdoviruses,
paramyxoviruses and arenaviruses, in part by impeding viral exit
from the cell, and by stimulating signaling that leads to NF-kB
activation (48, 70–72). BST2 is antagonized by the HIV protein
Vpu, the Kaposi’s sarcoma herpesvirus (KSHV) K5 protein and
Ebola virus glycoprotein (48, 73, 74). In CD4+ T cells, excluding
MHCmolecules, only 10 proteinswere stimulated by IFNa2a at the
cell surface. Inaddition toBST2,CNPalsohas antiviral activity (60),
suggesting that the other eight IFNa2a-stimulated CD4+ T cell
proteinsmightbeparticularly enriched innovel cell surfaceantiviral
factors. ECE1 was one of the most highly upregulated proteins
quantified in all five CD4+ T cell donations, and was not
upregulated in monocytes. We previously determined that ECE1
is downregulated by the human cytomegalovirus US2 protein (28,
75, 76) and is modestly downregulated at the plasma membrane
during infection with HIV (77). Further investigation will be
required to determine whether ECE1 has the ability to restrict
viruses. ECE1 is a zinc metalloendopeptidase, with the primary
functionof cleavageof endothelin to itsmature vasoactive form. It is
also able to cleave other peptides (78), and localizes to endosomes in
addition to the plasma membrane, where it has roles in receptor
recycling and re-sensitisation for substance P and TLR9 (79–81).
Potential mechanisms of viral restriction by this molecule might
thus include cleavage of viral proteins or host proteins necessary for
infection, or alternatively roles in stimulating host immunity.
Other than HLAs and BST2, TMEM123 was the only protein
consistently upregulated in both primary monocytes and CD4+
T cells by IFNa2a. This might provide a novel pan-leukocyte
marker for IFNa2a stimulation in addition to another candidate
antiviral factor. TMEM123 has so far been poorly characterized;
also known as Porimin, it was originally identified due to the
ability of anti-porimin antibody to stimulate oncotic cell death in
Jurkat T cells (82, 83). Generation of new resources to further
validate this finding at the protein level will be a necessary first
step in future investigations.
TMEM123, BST2, and HLA molecules were some of the most
consistently IFN-stimulated proteins, both between cell types and
also betweendonors.While cell surfaceproteomeswere remarkably
invariant between different donors, much greater variability was
observed between donor leukocytes in responses to IFNa2a
stimulation, particularly in CD4+ T cells. Possible explanations
for this phenomenon include (a) heterogeneity in the CD4+ T cell
populations examined between different donors (84); (b)
differential activation of STAT proteins and IFN signaling
pathways between donors, or polymorphisms in the promotors or
coding regions of IRFs, JAK or STAT proteins (6); or (c) a lack of
substantial IFNa2a response in a large proportion of CD4+ T cell
proteins meaning that many proteins studied exhibited relatively
small changes in expression. Although in this investigation our
focus was on identifying protein changes that were most consistentFrontiers in Immunology | www.frontiersin.org 12between different donors, it may nevertheless be valuable to
investigate proteins that exhibit more variable inter-donor
changes. Side effects and efficacy of IFN-based therapies for viral
hepatitis and cancers are known to vary between patients, which
may partly be explained by differences in cellular responses to
treatment (85–87). A larger study would be required to
comprehensively characterize the true extent of donor-to-donor
variability for such molecules.
An alternative strategy for identifying the most biologically
important molecules that are stimulated by IFNa2a could
combine our measurements of cell surface protein abundance
and IFNa2a-stimulated fold change. For example, intracellular
adhesion molecule 1 (ICAM1) did not meet criteria for IFNa2a
stimulation in CD14+ monocytes, only exhibiting an average
1.27-fold change in comparison to unstimulated cells. However,
as a highly abundant protein at the cell surface, accounting for
1.1% of cell surface molecules in CD14+ monocytes, the change
in number of ICAM1 molecules at the cell surface upon IFNa2a
stimulation would be considerably greater than other proteins of
low abundance but exhibiting higher absolute IFN-simulated
fold changes (for example, SIGLEC-1, 2.4-fold change, 0.0007%
of CD14+ monocyte cell surface). Such analysis could highlight a
different set of IFNa2a-stimulated proteins.
In this study, we have provided a comprehensive map of the
cell surface of resting and IFNa2a-stimulated primary leukocytes
from multiple donors, complementing and substantially
extending previous transcriptomic studies. Understanding how
IFNa2a differentially modulates the surface of immune cells will
enable a more complete understanding of the IFN response,
identifying candidate cellular antiviral factors, and factors which
may predict individual responses to IFN-based therapies.DATA AVAILABILITY STATEMENT
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